Video
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
Author(s):
Video Player is loading.
In this interview, Jason M. Hafron, MD, recaps the biggest advances in the prostate cancer treatment paradigm in 2022. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of Urology at the William Beaumont School of Medicine, Oakland University; and the director of Robotic Surgery at Beaumont Hospital Royal Oak in Michigan.
Related Videos
Study findings highlight gender gaps in oncology authorship and citation
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
Related Content
